Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J.…
Browsing: Acute Myelogenous Leukemia
Earn CME: https://www.naccme.com/program/19-cpc-101-4 This webcast features a presentation by Dr. Amir T. Fathi on best practices for the integration of…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://www.naccme.com/program/19-lm-01 In this webcast from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, offers his impression of the pivotal clinical data that lead…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber shares thoughts on current treatment strategies for elderly acute myeloid leukemia…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber elaborates on prognostic factors and the relationship to outcomes in acute…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber offers his impression of the landscape for FLT3 inhibition in acute…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber provides opinion on whether all acute myeloid leukemia (AML) patients should…
Richard Stone, MD, Physician, Hematologic Oncology, Internal Medicine, @DanaFarber describes the landscape of mutations and targeted therapy in acute myeloid…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer discusses the prognostic factors in acute myeloid leukemia…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer offers her overall impression on the changing FLT3…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether there are emerging mutations in FLT3…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether all acute myeloid leukemia (AML) patients…
Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine @UCSFMedicine tells us about the outcomes of the Phase…
Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses prognostic…
Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses some…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews provides insight on current treatment strategies for…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews describes the targeted therapy landscape in acute…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews explains how the treatment of acute myeloid…
Courtney DiNardo, MD Associate Professor, Department of Leukemia, Division of Cancer Medicine, @MDAndersonNews considers whether intensive chemotherapy should be used…
Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical…
Briggs Morrison, MD Chief Executive Officer of @Syndax discusses important details to note in this study. ___________ Syndax Pharmaceuticals, Inc.…
Briggs Morrison, MD Chief Executive Officer of @Syndax answers how likely is this to translate into being beneficial for patients…
Moleculin Biotech, Inc., (Nasdaq:Â MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates…
Briggs Morrison, MD Chief Executive Officer of @Syndax discusses a preclinical study on the activity of menin-MLL inhibition for the…
Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals’ lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with…
Abby Statler, MD of @ClevelandClinic answers if racial disparities in AML are associated with organ dysfunction.
Saro Armenian, DO of @cityofhope discusses the long term morbidity by survivors of AML treated with blood or marrow transplantation.
Aziz Nazha, MD of @CleClinicMD discusses a personalized prediction model to risk stratify patients with AML.
Eunice Wang, MD of @RoswellPark discusses cladribine, cytarabine, granulocyte colony stimulating factor ± mitoxantrone (CLAG ± M) is highly effective…
Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK…
No evidence of cardiotoxicity to date; 40% of 10 patients dosed at ≥120 mg/m² demonstrate efficacy; trial progresses in Europe…
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium”) today announced key interim findings from the pivotal Phase 3 SIERRA trial of…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on how myelodysplastic syndrome (MDS) patients who…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School discusses the recent wave of approvals in AML…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on the importance of the updated data…
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School elaborates on the phase III study of uproleselan…
Earn CME: https://naccme.com/program/7331 In this presentation from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Earn CME: https://naccme.com/program/7331 In this presentation from the ‘Looking to the Future With Hope: Advances in the Treatment of AML’…
Guillermo Garcia-Manero, MD Of The MD Anderson Cancer Center Discusses Hypomethylating Agents In Myeloid Disorders: Lower Doses Of Decitabine And…
Guillermo Garcia-Manero, MD Of The MD Anderson Cancer Center Discusses Should We Check If The Donor Has A Mutation: Depends…
Dr. Charles Craddock, MD discusses Graft V Host disease when combining Lenalidomide + Azacitidine
Charles Craddock MD PhD @charliecraddock of Queen Elizabeth Hospital discusses the Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in…
Earn CME credit for this activity: https://www.naccme.com/program/2018-802-04 This on-demand webcast examines the latest clinical and pharmacoeconomic data surrounding emerging therapies…
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Whats New In AML Transplants. At MOASC Oncology…
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Strategies To Treat AML. At MOASC Oncology Summit…
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Elaborating On Drug Approvals In AML. At MOASC…
Gary Schiller, M.D. Professor of Medicine Division of Hematology/Oncology At UCLA, Discusses Approaches Seen In AML. At MOASC Oncology Summit…